StockTitan

@stocktitan.net

3 weeks ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 Announced

#IVVD Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

www.stocktitan.net/news/IVVD/invivyd-report...

StockTitan

@stocktitan.net

2 months ago

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention Invivyd (Nasdaq: IVVD) announced a national multimedia education partnership with champion skier Lindsey Vonn to raise public awareness about antibodies and infectious disease prevention. The campaign is planned to launch in early Spring 2026, with Vonn serving as the public spokesperson to connect antibody science to health and wellness. Vonn, a decorated Olympian and 84-time World Cup winner who returned to competition in 2024 and qualified in December for the Milan Cortina 2026 Olympic Winter Games, will help translate antibody concepts into accessible guidance for the American public.

#IVVD Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

www.stocktitan.net/news/IVVD/invivyd-announ...

StockTitan

@stocktitan.net

2 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 Invivyd (Nasdaq: IVVD) and the SPEAR Study Group plan a Phase 2 trial of monoclonal antibody VYD2311 to evaluate safety, translational biology, and exploratory clinical efficacy in people with Long COVID or COVID vaccine injury, with initiation expected mid-2026. The randomized, double-blind, placebo-controlled design will test multiple long-term high doses of VYD2311 and enroll participants who demonstrate persistent infection or antigenemia where technologically detectable.VYD2311 has shown in vitro antiviral activity across all clinically recorded SARS-CoV-2 variants tested since the Wuhan strain. Further trial details and clinicaltrials.gov registration are expected to be posted in coming months.

#IVVD Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

www.stocktitan.net/news/IVVD/invivyd-and-sp...

StockTitan

@stocktitan.net

2 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025

#IVVD Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

www.stocktitan.net/news/IVVD/invivyd-report...

StockTitan

@stocktitan.net

3 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. Fast

#IVVD Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

www.stocktitan.net/news/IVVD/invivyd-earns-...

StockTitan

@stocktitan.net

3 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated A second arm will evaluate

#IVVD Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

www.stocktitan.net/news/IVVD/invivyd-announ...

StockTitan

@stocktitan.net

4 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platform VBY329 meets Invivyd’s target profile of higher potency and improved barrier to resistance compared

#IVVD Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

www.stocktitan.net/news/IVVD/invivyd-announ...

StockTitan

@stocktitan.net

4 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre-funded

#IVVD Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/IVVD/invivyd-announ...

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Most searched small-cap stocks, Mon Nov 17th - #RXRX #LAC #SGBX #HIVE #ANVS #SGML #IVVD #DNN #LAES #CYPH #ZYME #WRD #QUBT #PLUG #PEBO #ONDS #OBE #ESPR #CLSK #AI - More: crystalequityresearch.com/most-searche... - #smallcap

StockTitan

@stocktitan.net

4 months ago

Invivyd Announces Proposed Public Offering of Common Stock Invivyd (Nasdaq: IVVD) on November 17, 2025 announced an underwritten public offering of shares of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of the shares sold. All shares are being offered by Invivyd and the offering is subject to market conditions; timing, size and terms are not assured.The company said it intends to use net proceeds, together with existing cash, for commercial preparedness for VYD2311, continued R&D for RSV and measles programs, SPEAR Study Group efforts on monoclonal antibody effects for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and general corporate purposes.

#IVVD Invivyd Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/IVVD/invivyd-announ...

Stock Master

@stockmaster70.bsky.social

4 months ago

📢 Stocks Trending NOW: #TSLA #MSTR #CDTX #COIN #NVDA #IVVD #AVXL #WMT #ASBP #HOOD

StockTitan

@stocktitan.net

4 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter October 2025 ending cash and cash equivalents of over $100 million; ended Q3 2025 with $85.0 million in cash and cash equivalents after

#IVVD Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/IVVD/invivyd-report...

StockTitan

@stocktitan.net

5 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data anticipated mid-2026 DECLARATION is a Phase 3, randomized, placebo-controlled

#IVVD Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

www.stocktitan.net/news/IVVD/invivyd-announ...

Market Wire News

@marketwirenews.com

7 months ago

Breaking News: ( NASDAQ: #IVVD ) Invivyd to Participate in Upcoming Investor Conferences

Stock Master

@stockmaster70.bsky.social

7 months ago

📢 Stocks Trending NOW: #GPRO #AMD #TLRY #LLY #IBKR #SATS #NVDA #IVVD #BYND #OPAD

StockTitan

@stocktitan.net

7 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants Invivyd (Nasdaq: IVVD) has announced the pricing of a $50 million public offering, consisting of 74,811,404 shares of common stock at $0.52 per share and pre-funded warrants for 21,342,442 shares at $0.5199 per warrant.The company has granted underwriters a 30-day option to purchase up to 14,423,076 additional shares. The offering, managed by Cantor as sole book-runner, is expected to close around August 22, 2025. Proceeds will fund the VYD2311 clinical program, research in RSV and measles, SPEAR Study Group efforts for Long COVID research, and general corporate purposes.

#IVVD Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/IVVD/invivyd-announ...

StockTitan

@stocktitan.net

7 months ago

Clinical-Stage Biotech Invivyd Announces Stock Offering to Advance COVID, RSV Pipeline Programs Invivyd launches common stock offering to fund VYD2311 clinical program, RSV research, and SPEAR Study Group efforts for Long COVID research. Cantor Fitzgerald leads as sole book-runner.

#IVVD Invivyd Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/IVVD/invivyd-announ...

StockTitan

@stocktitan.net

7 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”) Invivyd (NASDAQ:IVVD) has announced that its COVID-19 antibody PEMGARDA® (pemivibart) and its next-generation candidate VYD2311 maintain strong neutralizing activity against the dominant XFG ("Stratus") SARS-CoV-2 variant. The company reports that COVID-19 cases are rising, with high viral activity in 12 states and growing infections in 34 states according to CDC data.PEMGARDA, which is FDA-authorized for pre-exposure prophylaxis in certain immunocompromised patients, has demonstrated consistent effectiveness against all clinical variants since the Omicron BA.2 lineage. The company will submit new in vitro neutralization data to the FDA for inclusion in PEMGARDA's Healthcare Provider Fact Sheet.

#IVVD Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

www.stocktitan.net/news/IVVD/invivyd-announ...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Invivyd Revenue Jumps 413 Percent in Q2 | The Motley Fool

#IVVD #7e3afa25-2023-4e8d-8daa-08a00337e88e #data-news

Origin | Interest | Match

StockTitan

@stocktitan.net

7 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights Invivyd (NASDAQ: IVVD) reported Q2 2025 financial results, highlighting $11.8 million in PEMGARDA® net product revenue, representing 413% year-over-year growth. The company announced positive Phase 1/2 data for VYD2311, their COVID-19 monoclonal antibody candidate, demonstrating favorable safety and a 76-day half-life for intramuscular administration.The FDA has aligned on a rapid pathway to full approval (BLA) for VYD2311. The company's pipeline expansion includes RSV and measles candidates, with updates expected in Q3 and Q4 2025. Financial results showed a net loss of $14.7 million ($0.12 per share), improved from $47.2 million loss in Q2 2024, with $34.9 million in cash as of June 30, 2025.

#IVVD Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/IVVD/invivyd-report...

StockTitan

@stocktitan.net

8 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome Invivyd (Nasdaq: IVVD) has announced that Dr. Akiko Iwasaki, Professor of Immunobiology at Yale School of Medicine, has joined the SPEAR Study Group. The group was established to investigate the biology and clinical implications of persistent spike protein from SARS-CoV-2 virus and COVID-19 vaccines.Dr. Iwasaki, co-Lead Investigator of the Yale COVID-19 Recovery Study, brings expertise in viral pathogenesis and post-viral conditions. The SPEAR Study Group was formed following reports that PEMGARDA® (pemivibart), Invivyd's FDA-authorized monoclonal antibody, showed potential benefits in Long COVID cases. The group plans to conduct clinical trials to evaluate monoclonal antibodies, including VYD2311, for treating Long COVID and Post-Vaccination Syndrome (PVS).

#IVVD Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

www.stocktitan.net/news/IVVD/scientist-dr-a...

StockTitan

@stocktitan.net

10 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA ® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network ® (NCCN ®) Clinical Practice Guidelines in Oncology for B-Cell

#IVVD Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

www.stocktitan.net/news/IVVD/invivyd-announ...

StockTitan

@stocktitan.net

10 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 Invivyd (NASDAQ: IVVD) commends the FDA's new approach to evaluating COVID-19 medical interventions, particularly regarding vaccine boosters and monoclonal antibody treatments. The FDA now acknowledges uncertainty in COVID-19 vaccine booster efficacy and encourages manufacturers to conduct randomized, placebo-controlled trials. Invivyd's CANOPY Phase 3 trial of pemivibart demonstrated an 84% reduction in COVID-19 risk compared to placebo over six months, significantly exceeding the FDA's 30% threshold for "meaningful" protection. The company plans to advance improved antibodies for more scalable protection and expects to provide updates on their next-generation monoclonal antibody VYD2311 this quarter. Invivyd aims to engage with the FDA on expedited development pathways for high-risk populations.

#IVVD Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

www.stocktitan.net/news/IVVD/invivyd-commen...

StockTitan

@stocktitan.net

10 months ago

Invivyd Urges FDA to Revolutionize COVID-19 Prevention: Calls for Major Shift from Vaccines to Antibody Treatments New petition challenges FDA's approach to COVID-19 prevention, proposing significant changes in how vaccines and antibody treatments are evaluated. See proposed reforms.

#IVVD Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

www.stocktitan.net/news/IVVD/invivyd-files-...

StockTitan

@stocktitan.net

10 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles Invivyd (NASDAQ: IVVD) has launched a discovery program for a measles monoclonal antibody (mAb) treatment, responding to healthcare providers' requests for treating active measles infections and post-exposure prophylaxis. The company aims to identify a preclinical candidate in 2025, with a progress update expected by year-end. Currently, there are no approved therapies for measles, with existing options limited to Vitamin A and immune globulin (IVIG), both having significant limitations. With over 20 million unvaccinated Americans and declining vaccination rates, the U.S. risks losing its measles elimination status. The proposed mAb treatment could offer advantages including high neutralizing capability, fewer toxicities, and potential use as prophylaxis for at-risk populations, including young children, immunocompromised individuals, and the elderly.

#IVVD Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

www.stocktitan.net/news/IVVD/invivyd-announ...